1887
Surveillance Open Access
Like 0

Abstract

Background

Invasive meningococcal disease (IMD) epidemiology has fluctuated over the past 25 years and varies among serogroups, age groups and geographical locations.

Aim

This study analysed the evolution of European IMD epidemiology from 2008 to 2017 to identify trends.

Methods

Reported number of IMD cases and associated incidence were extracted from the European Centre for Disease Prevention and Control Surveillance Atlas for Infectious Diseases for individual European countries. Epidemiology and its evolution were analysed by serogroup and age group.

Results

Overall IMD incidence decreased by 34.4% between 2008 and 2017. Serogroup B remained predominant in 2017; despite a 56.1% decrease over the 10-year period, the rate of decrease has slowed in recent years and varies by age group. Serogroup C was the second most prevalent serogroup until 2016. Its incidence decreased among individuals aged 1–24 years, the main population targeted by MenC vaccination campaigns, but increases have occurred in other age groups. Incidences of serogroups W and Y were low but increased by > 500% and > 130% (to 0.10 and 0.07/100,000) respectively, from 2008 to 2017. Considering all serogroups, a marked modification of the evolution trends by age group has occurred, with increases in incidence mainly affecting older age groups.

Conclusion

Although the overall IMD incidence decreased in Europe between 2008 and 2017, increases were observed for serogroups W and Y, and in the older population when considering all serogroups. It may be necessary to adapt current vaccination strategies to reflect epidemiological changes and their likely future evolution.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.3.2002075
2022-01-20
2022-09-27
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.3.2002075
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/3/eurosurv-27-3-3.html?itemId=/content/10.2807/1560-7917.ES.2022.27.3.2002075&mimeType=html&fmt=ahah

References

  1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-88.  https://doi.org/10.1056/NEJM200105033441807  PMID: 11333996 
  2. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.  https://doi.org/10.1016/S0140-6736(06)67932-4  PMID: 16458763 
  3. Centers for Disease Control and Prevention (CDC). Enhanced meningococcal disease surveillance report, 2017. Atlanta: CDC. [Accessed: 10 Aug 2020]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf
  4. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease: annual epidemiological report for 2017. Stockholm: ECDC; 2019. Available from: https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf
  5. Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421-38.  https://doi.org/10.1007/s40121-018-0213-2  PMID: 30267220 
  6. Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H, Nasiri MJ, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. Microb Pathog. 2019;134:103571.  https://doi.org/10.1016/j.micpath.2019.103571  PMID: 31163252 
  7. Kriz P, Wieffer H, Holl K, Rosenlund M, Budhia S, Vyse A. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st century. Expert Rev Vaccines. 2011;10(10):1477-86.  https://doi.org/10.1586/erv.11.117  PMID: 21988310 
  8. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31(1):101-7.  https://doi.org/10.1111/j.1574-6976.2006.00053.x  PMID: 17168998 
  9. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58-67.  https://doi.org/10.1016/S0264-410X(01)00299-7  PMID: 11587814 
  10. Aguilera JF, Perrocheau A, Meffre C, Hahné S, W135 Working Group. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8(8):761-7.  https://doi.org/10.3201/eid0808.010422  PMID: 12141959 
  11. Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578-85.  https://doi.org/10.1093/cid/ciu881  PMID: 25389259 
  12. Fazio C, Neri A, Vacca P, Ciammaruconi A, Arghittu M, Barbui AM, et al. Cocirculation of Hajj and non-Hajj strains among serogroup W meningococci in Italy, 2000 to 2016. Euro Surveill. 2019;24(4):1800183.  https://doi.org/10.2807/1560-7917.ES.2019.24.4.1800183  PMID: 30696530 
  13. Mulhall RM, Bennett DE, Bratcher HB, Jolley KA, Bray JE, O’Lorcain PP, et al. cgMLST characterisation of invasive Neisseria meningitidis serogroup C and W strains associated with increasing disease incidence in the Republic of Ireland. PLoS One. 2019;14(5):e0216771.  https://doi.org/10.1371/journal.pone.0216771  PMID: 31141820 
  14. Krone M, Gray S, Abad R, Skoczyńska A, Stefanelli P, van der Ende A, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14):1800245.  https://doi.org/10.2807/1560-7917.ES.2019.24.14.1800245  PMID: 30968827 
  15. World Health Organization (WHO). Menigitis. Geneva: WHO; 2021. Available from: http://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis
  16. La EM, Talbird SE, Kanadanian KV, Huang L, Fain J, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019;15(4):978-86.  https://doi.org/10.1080/21645515.2018.1556074  PMID: 30526279 
  17. European Centre for Disease Prevention and Control (ECDC). Meningococcal disease: recommended vaccinations. Stockholm: ECDC. [Accessed: 10 Aug 2020]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1
  18. Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013;31(41):4477-86.  https://doi.org/10.1016/j.vaccine.2013.07.083  PMID: 23933336 
  19. Superior Health Council (SHC). Meningococcal vaccination. Brussels: SHC. [Accessed: 10 Aug 2020]. Available from: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/shc_9485_meningococcal_vaccination_2019_1.pdf
  20. Diana A, Iten A, Landry P, Bouvier Gallacchi M. [Update of the 2019 Swiss immunization schedule 7 new recommendations and review of practical implications for health professionals]. Rev Med Suisse. 2019;15(660):1521-5. French. PMID: 31496178 
  21. World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2019 global summary. Geneva: WHO. [Accessed: 21 Jan 2020]. Available from: http://apps.who.int/immunization_monitoring/globalsummary
  22. Spanish Ministry of Health. Recomendaciones de vacunación frente a la enfermedad meningocócica invasiva. [Vaccination recommendations against invasive meningococcal disease]. Madrid: Ministerio de Sanidad; 2019. Spanish. Available from: https://www.mscbs.gob.es/en/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf
  23. Federal Ministry Republic of Austria. Impfplan Österreich 2021. [Vaccination schedule Austria 2021]. Wien: Sozialministerium. [Accessed: 24 Dec 2021]. German. Available from: https://www.sozialministerium.at/Themen/Gesundheit/Impfen/Impfplan-%C3%96sterreich.html
  24. Vetter V, Baxter R, Denizer G, Sáfadi MA, Silfverdal SA, Vyse A, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641-58.  https://doi.org/10.1586/14760584.2016.1130628  PMID: 26651380 
  25. Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309-17.  https://doi.org/10.1056/NEJMoa1901229  PMID: 31971676 
  26. European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Stockholm: ECDC. [Accessed: 11 Feb 2019]. Available from: https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases
  27. European Centre for Disease Prevention and Control (ECDC). Introduction to the annual epidemiological report. Stockholm: ECDC. [Accessed: 16 Jun 2021]. Available from: https://www.ecdc.europa.eu/en/all-topics-z/surveillance-and-disease-data/annual-epidemiological-reports/introduction-annual
  28. Eurostat. Demography, population stock and balance. Luxembourg: Eurostat. [Accessed: 3 Sep 2019]. Available from: https://ec.europa.eu/eurostat/web/population-demography-migration-projections/data/main-tables
  29. The R Foundation. The R project for statistical computing. Vienna: R Foundation of Statistical Computing. [Accessed: 10 Aug 2020]. Available from: https://www.r-project.org
  30. Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15-30.  https://doi.org/10.1080/14760584.2019.1557520  PMID: 30526162 
  31. Sridhar S, Greenwood B, Head C, Plotkin SA, Sáfadi MA, Saha S, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334-46.  https://doi.org/10.1016/S1473-3099(15)00217-0  PMID: 26453240 
  32. MacLennan J. Meningococcal carriage and teenage behaviour at periods of high and low meningococcal disease incidence. Presented at: International Pathogenic Neisseria Conference (IPNC), September 23-28, 2018; Monterey, CA, United States. Available from: https://neisseria.org/ipnc/2018/IPNC2018_abstracts.pdf
  33. Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. Lancet Infect Dis. 2017;17(7):754-62.  https://doi.org/10.1016/S1473-3099(17)30170-6  PMID: 28366725 
  34. Abad R, López EL, Debbag R, Vázquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461-70.  https://doi.org/10.1017/S0950268814001149  PMID: 24831052 
  35. Lahra MM, Hogan TR. National Neisseria Network A. Australian Meningococcal Surveillance Programme annual report, 2019. Commun Dis Intell. 2018;2020:44.
  36. Knol MJ, Hahné SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2(10):e473-82.  https://doi.org/10.1016/S2468-2667(17)30157-3  PMID: 29253430 
  37. Public Health England (PHE). Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018 to 2019. London: PHE; 2019. Available from: https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-in-2018-to-2019
  38. Public Health England (PHE). Invasive meningococcal disease in England. Annual report for 2018 to 2019 supplementary data tables. London: PHE; 2019. Available from: https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-in-2018-to-2019
  39. Taha MK, Gaudelus J, Deghmane AE, Caron F. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother. 2020;16(10):2518-23.  https://doi.org/10.1080/21645515.2020.1729030  PMID: 32209010 
  40. Eurostat. Population structure and ageing. Luxembourg: Eurostat. [Accessed: 10 Aug 2020]. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php/Population_structure_and_ageing
  41. Lucidarme J, Scott KJ, Ure R, Smith A, Lindsay D, Stenmark B, et al. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016;21(45):30395.  https://doi.org/10.2807/1560-7917.ES.2016.21.45.30395  PMID: 27918265 
/content/10.2807/1560-7917.ES.2022.27.3.2002075
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error